CelLBxHealth plc, formerly ANGLE plc, spent the better part of two decades building a liquid-biopsy platform that, in 2022, achieved a genuine world first: US FDA clearance for a system harvesting circulating tumour cells from a blood draw. Yet by late 2025 the shares had fallen heavily, revenue was in retreat, and management concluded the research-led model wasn't the model that would sell it.
The Quick Version
- CelLBxHealth plc is the rebranded ANGLE plc; it trades on AIM as CLBX (formerly AGL) and on US OTCQB as ANPCF, having renamed in October 2025.
- Its core asset is the Parsortix PC1 Clinical System, a microfluidic platform that harvests circulating tumour cells from blood — the first such system to receive US FDA clearance (2022, for metastatic breast cancer).
- 2025 was difficult: revenue fell about 52%, losses widened and shares fell heavily, prompting a £6.8m fundraise and a cost-reduction programme.
- Under new leadership the company shifted to a commercialisation-first, partnership-led strategy branded 'CTC Intelligence', guiding to roughly 50% revenue growth in 2026 while near-term losses widen.
- This is a higher-risk turnaround story: execution, funding, reimbursement and leadership stability are the central uncertainties.
What CelLBxHealth Actually Does
A medical-diagnostics company in liquid biopsy — analysing tumour-derived material from a blood sample rather than a surgical tissue biopsy. Its Parsortix system is a microfluidic device separating circulating tumour cells (CTCs) largely by size and deformability, an 'epitope-independent' approach that doesn't require tumour cells to display a particular protein to be captured. Revenue comes from instrument and consumable sales, laboratory services, and pharma-services work supporting drug-development programmes and trials.
Why the FDA Clearance Matters
In 2022, the Parsortix PC1 Clinical System secured FDA clearance for use with metastatic breast cancer patients to capture and harvest CTCs from blood for subsequent analysis — described consistently as a world first. Importantly, the clearance covers harvesting; downstream analysis is typically performed by the user or a partner laboratory, shaping how the technology reaches patients and how the company earns from it.
The Rebrand and the Reason Behind It
In October 2025, ANGLE plc announced a strategy update and renaming to CelLBxHealth, accompanied by a ticker change and new board leadership to drive the 'CTC Intelligence' strategy — a shift from an internally-driven, research-heavy model toward a 'commercialisation-first' approach partnering with established clinical laboratories and pharma-services providers who already understand US regulatory and reimbursement pathways.
The urgency was underlined by trading: 2025 revenue fell roughly 52% year-on-year, with customer delays and slower-than-hoped adoption weighing on the top line, while losses widened. CelLBxHealth raised £6.8m through an oversubscribed placing and subscription, and set out a cost-reduction programme quantified at around £5.9m of savings.
Leadership Turbulence
Peter Collins was appointed CEO as part of the reset and articulated the partnership-led vision publicly, but the company subsequently announced his departure, with the board reiterating support for the CTC growth strategy — churn at the top that's a material feature of the story rather than a footnote.
The Numbers and the Guidance
The roughly 52% revenue decline in 2025, combined with widening losses, is characteristic of a company whose commercial traction has lagged its scientific achievements. Management has guided to around 50% revenue growth in 2026 and pointed to medium-term adjusted EBITDA ambitions, while cautioning that near-term losses are expected to widen as the strategy beds in.
Risks Worth Weighing
Commercial execution risk is paramount — the strategy depends on securing and scaling partnerships that have yet to prove they can deliver material, recurring revenue. Funding risk is real given recent losses. Reimbursement and clinical-adoption risk remains a structural feature of diagnostics, where even cleared products can struggle to achieve routine payment. Leadership stability is a specific concern following recent boardroom change.
What to Watch Next
Concrete, named commercial partnerships with clinical laboratories or pharmaceutical companies, particularly ones translating into disclosed revenue. Evidence that 2026 revenue is tracking towards the guided growth rate. Progress on cost savings and any expansion of the platform's regulatory footprint. Stabilisation of the leadership team.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...